Effectiveness of Systemic Antifungal Prophylaxis in Patients With Neutropenia After Chemotherapy: A Meta-Analysis of Randomized Controlled Trials

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2316-2336

  Ziakas, Panayiotis D ^a   Kourbeti, Irene Sl ^b   Mylonakis, Elefthe ^a   Voulgarelis, Michaerios ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Chalkida General Hospital   (Greece)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antifungal prophylaxis; Chemotherapy; Meta analysis; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PLACEBO; VORICONAZOLE;

CANDIDIASIS; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); MYCOSIS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIPIENT; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

ANTIFUNGAL AGENTS; DRUG THERAPY; HUMANS; MYCOSES; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79951829446     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.009     Document Type: Review

References (75)

1. Sipsas N.V., Lewis R.E., Tarrand J., et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752.
2. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
3. Robenshtok E., Gafter-Gvili A., Goldberg E., et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2007, 25:5471-5489.
4. Bow E.J., Laverdière M., Lussier N., et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002, 94:3230-3246.
5. Gøtzsche P.C., Johansen H.K. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997, 314:1238-1244.
6. Haynes R.B., McKibbon K.A., Wilczynski N.L., et al. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: Analytical survey. BMJ 2005, 330:1179. Hedges Team.
7. Wong S.S., Wilczynski N.L., Haynes R.B. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc 2006, 94:451-455.
8. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002, 34:7-14. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
10. Robins J., Breslow N., Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986, 42:311-323.
11. Diamond G.A., Bax L., Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578-581.
12. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
13. Bradburn M.J., Deeks J.J., Berlin J.A., Russell Localio A. Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26:53-77.
14. Harbord R.M., Egger M., Sterne J.A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006, 25:3443-3457.
15. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
16. Altman D.G., Bland J.M. Interaction revisited: The difference between two estimates. BMJ 2003, 326:219.
17. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
18. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008) 2008, The Cochrane Collaboration, Oxford, UK. J.P. Higgins, S. Green (Eds.).
19. O'Rourke K. Mixed means and medians: A unified approach to deal with disparate outcome summaries. In: Proceedings of the 4th Symposium on Systematic Reviews: Pushing the Boundaries; July 2-4, 2002; Oxford, UK.
20. Brincker H. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 1983, 26:242-247.
21. Estey E., Maksymiuk A., Smith T., et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 1984, 144:1562-1568.
22. Hansen R.M., Reinerio N., Sohnle P.G., et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med 1987, 147:710-712.
23. Wingard J.R., Vaughan W.P., Braine H.G., et al. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987, 83:1103-1110.
24. Samonis G., Rolston K., Karl C., et al. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 1990, 12(Suppl 3):S369-S373.
25. Benhamou E., Hartmann O., Noguès C., et al. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation?. Results of a randomized placebo-controlled trial. Bone Marrow Transplant 1991, 7:127-131.
26. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
27. Palmblad J., Lönnqvist B., Carlsson B., et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: More bacteraemias. J Intern Med 1992, 231:363-370.
28. Perfect J.R., Klotman M.E., Gilbert C.C., et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992, 165:891-897.
29. Winston D.J., Chandrasekar P.H., Lazarus H.M., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993, 118:495-503.
30. Vreugdenhil G., Van Dijke B.J., Donnelly J.P., et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993, 11:353-358.
31. Tollemar J., Ringdén O., Andersson S., et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993, 12:577-582.
32. Tollemar J., Ringdén O., Andersson S., et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: A randomized trial in bone marrow transplant recipients. Transplant Proc 1993, 25:1495-1497.
33. Tollemar J., Höckerstedt K., Ericzon B.G., et al. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: Results of two randomized double-blind studies. Transplant Proc 1994, 26:1833.
34. Chandrasekar P.H., Gatny C.M. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. J Antimicrob Chemother 1994, 33:309-318. Bone Marrow Transplantation Team.
35. Chandrasekar P.H., Gatny C.M. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 1994, 40:136-143. Bone Marrow Transplantation Team.
36. Riley D.K., Pavia A.T., Beatty P.G., et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994, 97:509-514.
37. Schaffner A., Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995, 172:1035-1041.
38. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
39. Yamaç K., Senol E., Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995, 71:284-286.
40. Kern W., Behre G., Rudolf T., et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: Results of a prospective randomized phase III study. Cancer 1998, 83:291-301. German AML Cooperative Group.
41. Kelsey S.M., Goldman J.M., McCann S., et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999, 23:163-168.
42. Menichetti F., Del Favero A., Martino P., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Clin Infect Dis 1999, 28:250-255. Gruppo Italiano Malattie Ematologiche dell' Adulto.
43. Rotstein C., Bow E.J., Laverdiere M., et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999, 28:331-340. Canadian Fluconazole Prophylaxis Study Group.
44. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
45. Nucci M., Biasoli I., Akiti T., et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000, 30:300-305.
46. Laverdière M., Rotstein C., Bow E.J., et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000, 46:1001-1008.
47. Kaptan K., Ural A.U., Cetin T., et al. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 2003, 9:40-45.
48. Penack O., Schwartz S., Martus P., et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: Results from a randomized, single-center trial. Ann Oncol 2006, 17:1306-1312.
49. Vehreschild J.J., Böhme A., Buchheidt D., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007, 55:445-449.
50. Rowan-Legg A., Weijer C., Gao J., Fernandez C. A comparison of journal instructions regarding institutional review board approval and conflict-of-interest disclosure between 1995 and 2005. J Med Ethics 2009, 35:74-78.
51. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
52. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy 2001, 3:41-54. CDC, Infectious Disease Society of America, and American Society of Blood and Marrow Transplantation.
53. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007, 78:275-282.
54. Hachem R., Hanna H., Kontoyiannis D., et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499.
55. Wingard J.R., Merz W.G., Rinaldi M.G., et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325:1274-1277.
56. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007, 44:402-409.
57. Almyroudis N.G., Segal B.H. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis 2009, 22:385-393.
58. Imhof A., Balajee S.A., Fredricks D.N., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
59. Marty F.M., Cosimi L.A., Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350:950-952.
60. Kontoyannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: A case control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
61. Chamilos G., Marom E.M., Lewis R.E., et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60-66.
62. Lionakis M.S., Lewis R.E., Torres H.A., et al. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005, 52:15-20.
63. Lekakis L.J., Lawson A., Prante J., et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: Two cases and review of the literature. Biol Blood Marrow Transplant 2009, 15:991-995.
64. Ellis M.E., Qadri S.M., Spence D., et al. The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures. J Antimicrob Chemother 1994, 33:1223-1228.
65. Kanda Y., Yamamoto R., Chizuka A., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000, 89:1611-1625.
66. Marr K.A., Seidel K., White T.C., Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309-316.
67. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001, 135:412-422. Itraconazole Neutropenia Study Group.
68. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever [published correction appears in N Engl J Med. 2007;356:760]. N Engl J Med 2002, 346:225-234. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
69. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009, 151:264-269. PRISMA Group, W64.
70. Cornely O.A., Ullmann A.J., Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003, 101:3365-3372.
71. Buchanan A.G., Riben P.D., Rayner E.N., et al. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome. Clin Invest Med 1985, 8:139-147.
72. Gøtzsche P.C., Johansen H.K. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2002, (4). CD002033.
73. Philpott-Howard J.N., Wade J.J., Mufti G.J., et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993, 31:973-984. Multicentre Study Group.
74. Rosenberg-Arska M., Dekker A.W., Branger J., Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 1991, 27:369-376.
75. Falagas M.E., Vardakas K.Z., Samonis G. Decreasing the incidence and impact of infections in neutropenic patients: Evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin 2008, 24:215-235.